ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

cliramitug

Also written as “ALXN2220” and “NI006”.

Its studies are mostly in Amyloidosis, led by 2 companies.

Drug pageCliramitug: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 15, 20235 company-led studies, 4 open or runningLicense: Neurimmune → Alexion (AstraZeneca), Mar 2022Next primary completion: Dec 6, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca33 open or runningphase 3since Nov 15, 2023Nov 15, 2023Dec 6, 2027phase 3 · NCT06183931
Neurimmuneits history only21 open or runningphase 2since Sep 15, 2025Mar 11, 2020none ahead
  • Named in AstraZeneca’s own pipeline as cliramitug, phase 3, as of Oct 30, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Mar 1, 2022Alexion (AstraZeneca) licensed it from NeurimmuneLicenseWorldwide rights · completed · AstraZeneca
  2. Nov 15, 2023First study: phase 3 study in AmyloidosisFirst studyNCT06183931 · 1,182 enrolled · United States, Argentina, Australia and more
  3. Feb 13, 2025Named cliramitugINNProposed as its International Nonproprietary Name in WHO's List 132 · before, ALXN2220, NI006
  4. May 12, 2026Phase 2 study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)NCT07608354 · 326 enrolled · United States, Canada, China and more
  5. Aug 18, 2026Phase 3 study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)NCT07789483 · 1,180 planned · United States, Argentina, Australia and more

Ahead

  1. Dec 6, 2027Primary completion: phase 3 study in AmyloidosisNCT06183931
  2. Feb 6, 2029Primary completion: phase 2 study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)NCT07608354
  3. Jul 11, 2030Primary completion: phase 3 study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)NCT07789483

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 AstraZeneca leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07789483Transthyretin Amyloid Cardiomyopathy (ATTR-CM) · United States, Argentina, Australia and more3Not yet recruitingJul 11, 20301,180
NCT07608354Transthyretin Amyloid Cardiomyopathy (ATTR-CM) · United States, Canada, China and more2Active, not recruitingFeb 6, 2029326
NCT06183931Amyloidosis · United States, Argentina, Australia and more3Active, not recruitingDec 6, 20271,182

How it is read

Names in the registry

  • “ALXN2220”, 4 entries
  • “NI006”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.